Powered by 
Google Übersetzer
Google Übersetzer
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2019.
Q1 - Summary of Results of Operations
Business Update
Tom Y. Lee, Chief Executive Officer, said that, “Our fiscal Q1 2020 revenue was negatively impacted by a reduction in sales of our raw material ingredient, SILVÉRION®, as well as timing of sales to a large distributor. During the current quarter, sales to our two largest food processors increased by 154%, as compared with the prior year. We anticipate sales of both PURE Control® and PURE® Hard Surface to continue to increase as new and existing customers continue to expand use of our unique food safety solutions. Based on information received by our customers, pending regulatory approvals, and the significant steps taken to reduce our overhead, we maintain our goal of cash-flow breakeven in fiscal Q3 2020.”
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2019 and Form 10-Q for the first fiscal quarter ended October 31, 2019. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
PURE Bioscience, Inc. |
||||||||||
Condensed Consolidated Balance Sheets |
||||||||||
|
|
October 31, 2019 |
|
July 31, 2019 |
||||||
|
|
(Unaudited) |
|
|
|
|
||||
Assets |
|
|
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
904,000 |
|
|
$ |
|
398,000 |
|
Accounts receivable |
|
|
220,000 |
|
|
|
373,000 |
|
||
Inventories, net |
|
|
162,000 |
|
|
|
177,000 |
|
||
Restricted cash |
|
|
75,000 |
|
|
|
75,000 |
|
||
Prepaid expenses |
|
|
30,000 |
|
|
|
18,000 |
|
||
Total current assets |
|
|
1,391,000 |
|
|
|
1,041,000 |
|
||
Property, plant and equipment, net |
|
|
333,000 |
|
|
|
362,000 |
|
||
Patents, net |
|
|
506,000 |
|
|
|
529,000 |
|
||
Total assets |
|
$ |
|
2,230,000 |
|
|
$ |
|
1,932,000 |
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
|
|
||
Accounts payable |
|
$ |
|
749,000 |
|
|
$ |
|
553,000 |
|
Accrued liabilities |
|
|
128,000 |
|
|
|
185,000 |
|
||
Total current liabilities |
|
|
877,000 |
|
|
|
738,000 |
|
||
Deferred rent |
|
|
— |
|
|
|
4,000 |
|
||
Total liabilities |
|
|
877,000 |
|
|
|
742,000 |
|
||
Commitments and contingencies |
|
|
|
|
|
|
|
|
||
Stockholders’ equity |
|
|
|
|
|
|
|
|
||
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding |
|
|
— |
|
|
|
— |
|
||
Common stock, $0.01 par value: 100,000,000 shares authorized, 79,994,402 shares issued and outstanding at October 31, 2019, and 76,732,334 shares issued and outstanding at July 31, 2019 |
|
|
800,000 |
|
|
|
768,000 |
|
||
Additional paid-in capital |
|
|
125,156,000 |
|
|
|
123,900,000 |
|
||
Accumulated deficit |
|
|
(124,603,000 |
) |
|
|
(123,478,000 |
) |
||
Total stockholders’ equity |
|
|
1,353,000 |
|
|
|
1,190,000 |
|
||
Total liabilities and stockholders’ equity |
|
$ |
|
2,230,000 |
|
|
$ |
|
1,932,000 |
|
PURE Bioscience, Inc. |
||||||||||
Condensed Consolidated Statements of Operations |
||||||||||
(Unaudited) |
||||||||||
|
|
Three months ended |
||||||||
|
|
October 31, |
||||||||
|
|
2019 |
|
2018 |
||||||
Net product sales |
|
$ |
|
398,000 |
|
|
$ |
|
590,000 |
|
Operating costs and expenses |
|
|
|
|
|
|
|
|
||
Cost of goods sold |
|
|
156,000 |
|
|
|
203,000 |
|
||
Selling, general and administrative |
|
|
1,290,000 |
|
|
|
2,853,000 |
|
||
Research and development |
|
|
82,000 |
|
|
|
97,000 |
|
||
Total operating costs and expenses |
|
|
1,528,000 |
|
|
|
3,153,000 |
|
||
Loss from operations |
|
|
(1,130,000 |
) |
|
|
(2,563,000 |
) |
||
Other income (expense) |
|
|
|
|
|
|
|
|
||
Interest expense, net |
|
|
(2,000 |
) |
|
|
(3,000 |
) |
||
Other income, net |
|
|
7,000 |
|
|
|
— |
|
||
Total other income (expense) |
|
|
5,000 |
|
|
(3,000 |
) |
|||
Net loss |
|
$ |
|
(1,125,000 |
) |
|
$ |
|
(2,566,000 |
) |
Basic and diluted net loss per share |
|
$ |
|
(0.01 |
) |
|
$ |
|
(0.04 |
) |
Shares used in computing basic and diluted net loss per share |
|
|
78,004,073 |
|
|
|
71,002,302 |
|
||
PURE Bioscience, Inc. |
||||||||||||||||||||||||
Condensed Consolidated Statement of Stockholders’ Equity |
||||||||||||||||||||||||
(Unaudited) |
||||||||||||||||||||||||
|
|
Common Stock |
|
Additional
|
|
Accumulated |
|
Total
|
||||||||||||||||
|
|
Shares |
|
Amount |
|
Capital |
|
Deficit |
|
Equity |
||||||||||||||
Balance July 31, 2019 |
|
|
76,732,334 |
|
|
$ |
|
768,000 |
|
|
$ |
|
123,900,000 |
|
|
$ |
|
(123,478,000 |
) |
|
$ |
|
1,190,000 |
|
Issuance of common stock in private placements, net |
|
|
2,862,068 |
|
|
|
28,000 |
|
|
|
802,000 |
|
|
|
— |
|
|
|
830,000 |
|
||||
Share-based compensation expense - stock options |
|
|
— |
|
|
|
— |
|
|
|
268,000 |
|
|
|
— |
|
|
|
268,000 |
|
||||
Share-based compensation expense - restricted stock units |
|
|
— |
|
|
|
— |
|
|
|
190,000 |
|
|
|
— |
|
|
|
190,000 |
|
||||
Issuance of common stock for vested restricted stock units |
|
|
400,000 |
|
|
|
4,000 |
|
|
|
(4,000 |
) |
|
|
— |
|
|
|
— |
|
||||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,125,000 |
) |
|
|
(1,125,000 |
) |
||||
Balance October 31, 2019 (Unaudited) |
|
|
79,994,402 |
|
|
$ |
|
800,000 |
|
|
$ |
|
125,156,000 |
|
|
$ |
|
(124,603,000 |
) |
|
$ |
|
1,353,000 |
|
|
|
Common Stock |
|
Additional
|
|
Accumulated |
|
Total
|
||||||||||||||||
|
|
Shares |
|
Amount |
|
Capital |
|
Deficit |
|
Equity |
||||||||||||||
Balance July 31, 2018 |
|
|
68,248,158 |
|
|
$ |
|
683,000 |
|
|
$ |
|
117,522,000 |
|
|
$ |
|
(116,924,000 |
) |
|
$ |
|
1,281,000 |
|
Issuance of common stock in private placements, net |
|
|
3,333,964 |
|
|
|
33,000 |
|
|
|
1,465,000 |
|
|
|
— |
|
|
|
1,498,000 |
|
||||
Share-based compensation expense - stock options |
|
|
— |
|
|
|
— |
|
|
|
1,002,000 |
|
|
|
— |
|
|
|
1,002,000 |
|
||||
Share-based compensation expense - restricted stock units |
|
|
— |
|
|
|
— |
|
|
|
741,000 |
|
|
|
— |
|
|
|
741,000 |
|
||||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,566,000 |
) |
|
|
(2,566,000 |
) |
||||
Balance October 31, 2018 (Unaudited) |
|
|
71,582,122 |
|
|
$ |
|
716,000 |
|
|
$ |
|
120,730,000 |
|
|
$ |
|
(119,490,000 |
) |
|
$ |
|
1,956,000 |
|
PURE Bioscience, Inc. |
||||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||||
(Unaudited) |
||||||||||
|
|
Three Months Ended |
||||||||
|
|
October 31, |
||||||||
|
|
2019 |
|
2018 |
||||||
Operating activities |
|
|
|
|
|
|
|
|
||
Net loss |
|
$ |
|
(1,125,000 |
) |
|
$ |
|
(2,566,000 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
||
Share-based compensation |
|
|
458,000 |
|
|
|
1,744,000 |
|
||
Amortization of stock issued for services |
|
|
4,000 |
|
|
|
19,000 |
|
||
Depreciation and amortization |
|
|
52,000 |
|
|
|
71,000 |
|
||
Interest expense on promissory note |
|
|
— |
|
|
|
1,000 |
|
||
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
||
Accounts receivable |
|
|
153,000 |
|
|
(78,000 |
) |
|||
Inventories |
|
|
15,000 |
|
|
(12,000 |
) |
|||
Prepaid expenses |
|
|
(16,000 |
) |
|
|
(32,000 |
) |
||
Accounts payable and accrued liabilities |
|
|
139,000 |
|
|
(206,000 |
) |
|||
Deferred rent |
|
|
(4,000 |
) |
|
|
(1,000 |
) |
||
Net cash used in operating activities |
|
|
(324,000 |
) |
|
|
(1,060,000 |
) |
||
Investing activities |
|
|
|
|
|
|
|
|
||
Purchases of property, plant and equipment |
|
|
— |
|
|
(8,000 |
) |
|||
Net cash used in investing activities |
|
|
— |
|
|
(8,000 |
) |
|||
Financing activities |
|
|
|
|
|
|
|
|
||
Net proceeds from the sale of common stock |
|
|
830,000 |
|
|
|
993,000 |
|
||
Net proceeds from the exercise of warrants |
|
|
— |
|
|
|
— |
|
||
Net cash provided by financing activities |
|
|
830,000 |
|
|
|
993,000 |
|
||
Net increase (decrease) in cash, cash equivalents, and restricted cash |
|
|
506,000 |
|
|
(75,000 |
) |
|||
Cash, cash equivalents, and restricted cash at beginning of period |
|
|
473,000 |
|
|
|
926,000 |
|
||
Cash, cash equivalents, and restricted cash at end of period |
|
$ |
|
979,000 |
|
|
$ |
|
851,000 |
|
|
|
|
|
|
|
|
|
|
||
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
904,000 |
|
|
$ |
|
776,000 |
|
Restricted cash |
|
$ |
|
75,000 |
|
|
$ |
|
75,000 |
|
Total cash, cash equivalents and restricted cash |
|
$ |
|
979,000 |
|
|
$ |
|
851,000 |
|
|
|
|
|
|
|
|
|
|
||
Supplemental disclosure of non-cash financing activities |
|
|
|
|
|
|
|
|
||
Conversion of promissory note and accrued interest from a related party to common stock |
$ |
— |
$ |
504,000 |
||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20191213005076/en/
